Quillivant XR (methylphenidate HCl) for extended-release oral suspension, 750 mg/150 mL (25mg/5mL...
FDA Drug Recall #D-0608-2017 — Class III — March 7, 2017
Recall Summary
| Recall Number | D-0608-2017 |
| Classification | Class III — Low risk |
| Date Initiated | March 7, 2017 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Pfizer Inc |
| Location | Peapack, NJ |
| Product Type | Drugs |
| Quantity | 11,862 units |
Product Description
Quillivant XR (methylphenidate HCl) for extended-release oral suspension, 750 mg/150 mL (25mg/5mL), Rx Only, Distributed by: NextWave Pharmaceuticals, Inc. A subsidiary of Pfizer Inc, New York, NY 10017 Manufactured by: Tris Pharma, Inc., Monmouth Junction, NJ 08852 (NDC 24478-205-25).
Reason for Recall
Failed Dissolution Specifications: Dissolution at 8 hour was out of specification at 12 month at 25 degree Celsius.
Distribution Pattern
Nationwide within US
Lot / Code Information
Lot #: 03216026A, Exp. 02/18
Other Recalls from Pfizer Inc
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0590-2025 | Class II | Vial Label: Epinephrine Injection, USP, 1mg/10m... | Aug 4, 2025 |
| D-0591-2025 | Class II | Vial Label: 8.4% Sodium Bicarbonate Injection, ... | Aug 4, 2025 |
| D-0607-2017 | Class III | Quillivant XR (methylphenidate HCl) for extende... | Mar 7, 2017 |
| D-0609-2017 | Class III | Quillivant XR (methylphenidate HCl) for extende... | Mar 7, 2017 |
| D-0800-2016 | Class III | Adult Robitussin PEAK COLD Cough & Chest Conges... | Feb 10, 2016 |
Frequently Asked Questions
Stop taking the medication and contact your pharmacist or doctor immediately. For Class I recalls, this is urgent. For Class II or III recalls, consult your doctor before stopping — abruptly discontinuing certain medications (blood pressure drugs, antidepressants, diabetes medications) can be more harmful than continuing while arranging a replacement. Check whether the recall applies to your specific lot number and expiration date. Return the product to your pharmacy and report any adverse effects to FDA MedWatch at 1-800-FDA-1088.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.